Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases Authors: Fatemeh Hosseini, Mohammadreza Mobinizadeh, William V Padula Published: 2026 ABSTRACT AbstractHealth technology assessment (HTA) informs evidence-based decision-making for resource allocation in healthcare; however, the topic selection phase that determines which technologies proceed to full assessment is underexplored and often lacks fairness and transparency, particularly disadvantaging orphan medicinal products (OMPs) for rare diseases. We drew on selectively identified literature and illustrative HTA experiences to advance an opinion-driven argument about equity in topic selection for OMPs, grouping insights into three domains: structural challenges, conceptual frameworks and policy strategies. Structural barriers in topic selection include a lack of institutionalised, participatory processes, overreliance on prioritisation criteria implicitly aligned with population-wide impact and minimal engagement with stakeholders representing the rare disease community, resulting in the systematic under-prioritisation of OMPs. Procedural and value frameworks, including multi-criteria decision analysis (MCDA), evidence-informed deliberative processes (EDPs), accountability for reasonableness (A4R), equity weighting and Health Equity Impact Assessment (HEIA), can help agencies incorporate social value and fairness before formal appraisal, but remain unevenly operationalised. Policy strategies such as equity-oriented horizon scanning, open nomination systems, and special pathways for OMPs are highlighted as feasible approaches to promote fairness. Achieving equity in HTA topic selection for OMPs requires both policy and cultural change, and embedding pluralistic value frameworks, engaging stakeholders and adopting specific policy tools are essential steps towards ensuring that rarity is met with heightened ethical attention rather than exclusion. Key Points for Decision Makers Topic selection is an underexamined but critical stage in health technology assessment (HTA), where orphan medicinal products (OMPs) are often excluded due to structural and procedural biases before formal appraisal occurs.Reliance on conventional cost-effectiveness expectations, limited stakeholder engagement and unstructured prioritisation processes can undermine transparency and fairness in HTA for rare diseases by filtering out OMPs early in the decision pathway.Embedding equity-oriented approaches such as structured prioritisation frameworks, participatory processes and dedicated pathways for OMPs can improve transparency, support fairer inclusion decisions and strengthen the legitimacy of HTA systems. Introduction Health technology assessment (HTA) is widely used to inform coverage and resource allocation decisions, yet one of its most consequential choices is often the least governed: which technologies are assessed in the first place. Many agencies operationalise HTA in three phases—topic selection, assessment and appraisal—but topic selection functions as a gatekeeping step that can determine visibility, legitimacy and eventual consideration, especially for orphan medicinal products (OMPs) [1, 2]. Our position is that OMPs are systematically filtered out upstream, not only by evidence constraints but also by selection criteria and routines implicitly optimised for population-wide impact. If equity is treated as something to address only during appraisal, rare disease technologies may never enter the evaluative pipeline at all. Topic selection generally includes identification/nomination, initial screening and prioritisation for full assessment [3]. The key equity failure point is often the nomination and routing gateway: technologies that do not reach, or are not prioritised within, this stage remain effectively invisible to subsequent assessment and appraisal processes. For OMPs, reliance on manufacturer submissions, weak rare disease horizon scanning and limited participatory nomination channels can prevent entry to the HTA pipeline altogether [4]. These challenges are amplified for OMPs, which treat small patient populations, involve high per-patient costs and often have limited clinical evidence. Conventional topic selection methods, which emphasise population-level burden of disease, cost-effectiveness and feasibility, systematically deprioritise these therapies [2, 5]. Ignoring social and ethical values such as unmet need, fairness and the societal value of innovation exacerbates inequities, particularly for marginalised patient groups [6]. Excluding OMPs at the topic selection stage raises distributive justice concerns, as patients with rare diseases may be overlooked even before their clinical or social value is assessed [2]. Orphan drug legislation provides important context. Whilst Orphan Drug Acts primarily incentivise research and development rather than guarantee reimbursement, their existence signals explicit policy recognition that rare diseases warrant special consideration. This recognition has indirect implications for HTA agenda-setting, reinforcing the ethical necessity of ensuring OMPs are not systematically filtered out at the topic selection stage [7]. Globally, HTA systems vary in how they structure and govern topic selection. In high-income countries (HICs), formalised criteria with broad stakeholder engagement allow for better integration of social and ethical considerations alongside technical evidence [8]. In contrast, low- and middle-income countries (LMICs) often rely on informal or reactive processes shaped by institutional constraints, political pressures or limited resources, which frequently exclude OMPs [3, 9, 10]. This Current Opinion emphasises that inequities affecting OMPs primarily emerge at the topic selection stage rather than downstream appraisal. Whilst much literature focusses on methodological challenges in evaluating OMPs during cost-effectiveness assessment, far less attention is given to how early agenda-setting decisions determine which technologies are considered. Topic selection is a critical ethical bottleneck, where implicit assumptions about value, efficiency and feasibility systematically disadvantage rare disease technologies. To address these gaps, this article examines structural barriers, conceptual approaches and operational strategies, exploring how rarity should influence early HTA agenda-setting and whether current practices systematically disadvantage OMPs. We therefore focus on topic selection as an upstream equity bottleneck. We summarise (i) structural barriers that reduce OMP visibility, (ii) decision frameworks that can make values explicit earlier and (iii) operational policy levers agencies can implement to prevent systematic upstream exclusion. Key Literature Using a purposive, non-systematic selection of key studies, we conducted an informed narrative synthesis structured around structural challenges, conceptual frameworks and operational strategies (Table 1). Table 1Key literature sourcesNo.TitleAuthorsYear1Key principles for the improved conduct of health technology assessments for resource allocation decisionsDrummond et al. [1]20082Is it the right topic? An overlooked stage in the institutionalization of health technology assessmentPeacocke et al. [2]20233Assessing the economic challenges posed by orphan drugsDrummond et al. [5]20074HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countriesNicod et al. [6]20195Topic selection process in health technology assessment agencies around the world: a systematic reviewQiu et al. [8]20226Health technology assessment in low- and middle-income countries: a landscape analysisBabigumira et al. [9, 10]20167Towards equity-oriented topic selection in health technology assessment for orphan drugs in Iran: a commentaryHosseini & Mobinizadeh [10]20258Topic identification, selection, and prioritisation for health technology assessment in selected countries: a mixed study designBidonde et al. [3]20249Considering equity in health technology assessment: an exploratory analysis of agency practices.Panteli et al. [11]201510The global landscape of country-level health technology assessment processes: a survey among 104 countriesMirelman et al. [12]202511Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest groupNestler-Parr et al. [13]201812Assessing the value of orphan drugs using conventional cost-effectiveness analysis: is it fit for purpose?Postma et al. [14]202213Exploring values of health technology assessment agencies using reflective multicriteria and rare disease caseGoetghebeur et al. [15]201714Applying multi-criteria decision making (MCDM) in health technology policy making: background, current challenges, and path to futureMobinizadeh et al. [16]202215Use of evidence-informed deliberative processes by health technology assessment agencies around the globeOortwijn et al. [17]202016Moving towards accountability for reasonableness: a systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case studyWagner et al. [18]201917Health equity considerations in cost-effectiveness analysis: insights from an umbrella reviewMuir et al. [19]2024 Key literature sources Structural Challenges in Topic Selection for OMPs Several structural barriers shape how HTA agencies identify and prioritise topics for assessment, particularly disadvantaging OMPs. These include reliance on evidence and criteria tailored to large patient populations and conventional cost-effectiveness metrics; the absence of institutionalised, transparent and participatory topic selection procedures; the dominance of industry submissions, media attention or political considerations in agenda-setting; limited mechanisms for proactively identifying emerging technologies for rare diseases; and insufficient integration of stakeholder engagement, especially patient and clinician input, at early stages of HTA [3, 4]. Topic selection criteria frequently privilege signals correlated with population-level impact and downstream evaluability—including broad burden of disease, predictable evidence pathways and anticipated affordability—thereby disadvantaging small-population technologies. Therefore, OMPs that serve limited patient populations and involve high per-patient costs are neglected—not because of a lack of value, but because current selection frameworks fail to capture their distinctive features or social importance [2]. Most HTA systems also lack institutionalised, transparent and participatory topic selection processes [12]. Instead, topic selection is frequently driven by industry submissions, media attention or political considerations rather than explicit public health priorities [3]. Furthermore, many systems do not establish proactive mechanisms to identify emerging or high-priority technologies for rare diseases, preventing these technologies from entering the nomination stage of HTA [13]. Stakeholder engagement is often not meaningfully embedded at the topic selection stage. Whilst some HICs have developed formal processes to involve patients, clinicians and payers early in the process, such mechanisms remain limited in many LMICs [3]. Patient organisations for rare diseases frequently lack institutional access, resources or technical capacity to contribute effectively to early HTA deliberations. Even where agencies express openness to engagement, limited time and analytical capacity may lead decision-makers to prioritise technologies that are easier to evaluate using conventional methods, further marginalising OMPs [20, 21]. Although formal cost-effectiveness evidence such as incremental cost-effectiveness ratio (ICER) estimates or quality-adjusted life year (QALY) based thresholds is typically generated at later stages of HTA, expectations about how OMPs are likely to perform against these criteria can still shape decisions during topic selection. In the absence of full economic evaluations, decision-makers may rely on proxy signals, such as anticipated high per-patient costs, small target populations and historically unfavourable cost-effectiveness profiles of similar technologies. As a result, downstream appraisal logics can indirectly influence which technologies are selected for assessment, reinforcing the systematic underrepresentation of rare disease treatments within HTA agendas [3, 14]. Institutional practices across HTA agencies illustrate how topic selection mechanisms can both acknowledge and constrain consideration of OMPs. In HICs, agencies such as the National Institute for Health and Care Excellence (NICE) employ horizon scanning and routing mechanisms, including the highly specialised technologies (HST) programme, to identify ultra-rare therapies early. Stakeholder engagement, including patient and clinician input, helps ensure that these therapies are not overlooked, although anticipated budget impact and service capacity continue to influence prioritisation [22]. In LMICs, including Thailand and Brazil, structured nomination processes aligned with national health priorities and fiscal constraints tend to disadvantage low-prevalence, high-cost technologies before formal assessment begins [23]. In Iran, topic selection relies heavily on manufacturer submissions, with minimal horizon scanning for rare diseases [10]. In Thailand, although prioritisation aligns with national health priorities, low-prevalence, high-cost technologies are often deprioritised due to budget constraints, limiting early consideration of OMPs [24]. Together, these examples suggest that equity challenges for rare diseases are often embedded in agenda-setting practices rather than arising solely at later appraisal stages. These structural barriers together reduce the likelihood that HTA agencies will consider rare diseases and their treatments. When this upstream filtering is routine and opaque, equity is not merely postponed, it is procedurally denied, because affected groups are excluded from the agenda-setting stage where public reasons, that is, the transparent and publicly defensible rationale for decisions, should be visible and contestable. These issues reflect not just methodological and institutional limitations, but also deeper concerns about whose values shape early stage decisions. To overcome them, agencies must develop both technical and ethical solutions, ones that treat rarity not as a limitation but as an opportunity for more inclusive and reflective decision-making [15]. Conceptual Frameworks for Embedding Equity The structural challenges identified above reveal systematic shortcomings in how HTA agencies identify and prioritise topics for assessment, particularly for OMPs. In response, several conceptual frameworks offer tools for embedding equity considerations directly into topic selection processes. These frameworks matter here because they force agencies to state, defend and, where appropriate, appeal the value judgements that otherwise remain implicit at the selection gate. Their relevance, however, varies across institutional contexts and levels of decision-making capacity [6, 10]. Multi-criteria decision analysis (MCDA) is frequently proposed as a means of broadening decision-making beyond cost-effectiveness by incorporating multiple dimensions of value. At the topic selection stage, its primary contribution lies in structuring deliberation about which technologies warrant assessment, rather than generating composite scores. For OMPs, MCDA can make visible criteria such as disease severity, unmet need and social concern that are often weakly represented in early prioritisation. However, without explicit safeguards, MCDA may formalise exclusion if criteria weight implicitly favours large populations or readily quantifiable outcomes, thereby reproducing structural biases rather than correcting them [16, 25]. Evidence-informed deliberative processes (EDPs) explicitly recognise that priority-setting involves both empirical evidence and social values. When applied to topic selection, EDPs can legitimise the inclusion of experiential knowledge from patients and clinicians, particularly when data are limited or uncertain. This approach is especially crucial for rare diseases, where meeting conventional evidence standards often proves challenging. Yet EDPs require sustained institutional capacity and stakeholder engagement, which may be challenging in resource-constrained settings [16, 26, 27]. Accountability for reasonableness (A4R) is particularly relevant to topic selection because it emphasises fairness in decision-making processes rather than outcomes alone. For rare diseases, A4R underscores the ethical importance of publicly articulated rationales for why certain technologies are included or excluded from HTA agendas. Its conditions of publicity, relevance and appeals can help expose implicit value judgements that disadvantage OMPs early on. Nonetheless, procedural fairness does not automatically ensure substantive inclusion, especially where evidentiary constraints remain significant [18, 28]. Health Equity Impact Assessment (HEIA) offers a structured approach to examining the differential effects of selecting or excluding special technologies across population groups. When applied at the topic selection stage, HEIA can help anticipate how agenda-setting choices may influence existing health inequities, which allows equity considerations to shape decisions before formal appraisal begins [29]. Equity weighting represents a more quantitative strategy, adjusting QALY-based evaluations to reflect differences in disease severity, age or socioeconomic disadvantage. Although typically applied at later appraisal stages, its underlying normative logic can inform topic selection by signalling that efficiency alone should not determine which technologies are considered worthy of assessment [19]. A related budgeting lens (e.g. program budgeting and marginal analysis) can also help make opportunity costs explicit, but is better treated as a complementary managerial tool than a primary framework for national topic selection [30]. Despite their promise, these frameworks face practical barriers, including limited availability of disaggregated data, uneven stakeholder capacity to participate in technical deliberations and political constraints on formalising transparent prioritisation rules. Consequently, no single framework offers a complete solution. Instead, their value lies in making explicit the ethical assumptions and trade-offs that are otherwise implicit in topic selection processes. Taken together, these approaches provide complementary tools for strengthening legitimacy, transparency and value pluralism in HTA agenda-setting. When strategically integrated, they can help ensure that rarity is not treated as a disqualifying characteristic at the earliest stages of decision-making, but as a prompt for more inclusive and ethically reflective priority-setting. Policy Strategies to Operationalise Equity in Topic Selection Translating conceptual frameworks into practice requires concrete policy instruments that support proactive and inclusive decision-making in HTA agencies. In practice, equity-oriented topic selection can be operationalised through three levers: (1) proactive identification; (2) participatory nomination; and (3) explicit routing and prioritisation rules. Horizon scanning is traditionally used to identify emerging technologies, but it is underutilised for promoting equity. Embedding equity-sensitive filters (e.g. targeting rare, severe, or underserved conditions) allows HTA bodies to identify and prioritise OMPs before they are excluded from early consideration [31]. Stakeholder engagement is critical to increase visibility for marginalised health needs. Whilst many HTA agencies rely on internal panels or manufacturer submissions, equitable topic selection requires input from patients, rare disease advocates, clinicians and public health professionals. Digital platforms, public calls for proposals and structured community engagement can help achieve this goal [32]. Structured prioritisation tools that integrate quantitative (e.g. scoring models) and qualitative (e.g. ethical deliberation) elements provide a transparent, balanced approach. The Netherlands has implemented deliberative equity frameworks that actively integrate stakeholder perspectives into HTA decision-making for rare diseases [26]. At the international level, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) rare disease Special Interest Group has proposed alternative criteria—disease severity, unmet need and ethical considerations—to guide prioritisation [13]. These tools should be adapted to local contexts but informed by international best practices to ensure legitimacy and consistency [33]. Special pathways or case-based exemptions for OMPs, guided by principles such as proportionality and unmet need, can prevent early exclusion of high-urgency, low-evidence technologies. Taken together, this underscores the importance of strengthening upstream decision‑making processes to ensure that considerations of equity, uncertainty and stakeholder perspectives are not deferred to later stages of HTA. Whilst horizon scanning and structured prioritisation may be more feasible in HICs, LMICs can start with open nomination systems and simplified, stakeholder-inclusive processes, providing a practical step towards equity despite limited data or analytic capacity. Such early efforts can help build institutional experience and public trust in the legitimacy of HTA decisions, gradually enabling more structured approaches over time. In summary, addressing the barriers OMPs face during topic selection requires both policy reform and a shift in the logic of prioritisation itself. Combining equity-focused horizon scanning, stakeholder engagement, hybrid prioritisation models and ethical pathways ensures that rare diseases are not only included in HTA agendas, but also equitably prioritised. Discussion This analysis highlights a fundamental but often underappreciated weakness in many HTA systems: topic selection operates as a powerful gatekeeping mechanism yet remains weakly theorised, poorly governed and largely insulated from explicit equity considerations. Whilst most HTA literature and reform agendas focus on improving appraisal methodologies for OMPs, our findings suggest that inequities frequently arise much earlier. The practical implication is straightforward: improving orphan-drug appraisal methods does not address equity if OMPs are screened out before appraisal begins. For rare disease technologies, exclusion or deprioritisation at the topic selection stage may effectively preclude assessment altogether, regardless of their potential social or clinical value. Early exclusion of OMPs is not merely a technical consequence of limited evidence or uncertainty. It reflects deeper structural features of topic selection systems. Even in the absence of formal cost-effectiveness evidence such as ICERs, decision-makers often rely on anticipatory judgments shaped by prior experience, policy norms and proxy signals such as expected high per-patient costs, small target populations and historically unfavourable cost-effectiveness profiles of similar technologies. Criteria favouring broad population impact, mature evidence bases and predictable appraisal performance implicitly privilege common conditions, rendering rare diseases systematically less visible within HTA agendas. This dynamic is particularly pronounced in LMICs, where topic selection processes are often informal, reactive and shaped by institutional convenience or political pressures rather than transparent criteria or stakeholder engagement [3, 9, 10]. In such contexts, rare disease communities frequently lack the institutional voice or policy salience required to influence early prioritisation decisions, perpetuating a cycle of neglect. Conceptual frameworks identified in this review offer important correctives to these structural limitations. They challenge narrow conceptions of value based solely on clinical or economic efficiency and foreground ethical considerations such as unmet need, disease severity, fairness and social legitimacy [1, 15, 17]. However, despite their promise, these frameworks are most often applied at the appraisal stage. Applying them earlier during topic selection could yield greater equity gains by shaping which technologies are considered in the first place. Rare diseases thus function as a stress test for HTA systems, exposing the value-laden nature of topic selection decisions that are often portrayed as neutral or administrative. Making these judgments explicit through transparent criteria, stakeholder involvement and structured deliberation is essential for enhancing legitimacy and accountability, particularly for marginalised or low-prevalence conditions [10]. Translating these insights into practice requires deliberate policy and institutional action. Equity-sensitive horizon scanning can proactively identify neglected areas of high unmet need, including rare diseases. Open and transparent topic nomination systems broaden participation by incorporating patient, clinician and civil society perspectives. Structured prioritisation tools that combine ethical reasoning with technical assessment support more inclusive and defensible agenda-setting decisions. In some settings, special pathways or case-based exemptions for OMPs can ensure that high-urgency, low-evidence technologies are not excluded prematurely [10, 13, 14]. Importantly, these measures do not guarantee positive reimbursement outcomes. Rather, they ensure that decisions about whether to assess OMPs are made transparently, consistently and with explicit attention to equity. Topic selection is thus a central ethical and procedural juncture in HTA, where early inclusion or exclusion decisions determine whose health needs are recognised. Strengthening governance and embedding equity at this stage aligns HTA practice with broader commitments to fairness and socially responsive priority-setting. Conclusions Fairness in HTA begins with the very first decision: what is worth assessing. If OMPs are routinely deprioritised at the selection gate, equity cannot be ‘repaired’ later through appraisal refinements. The goal is not guaranteed reimbursement, but procedurally legitimate inclusion: transparent nomination routes, equity-sensitive identification and defensible prioritisation rules that make trade-offs explicit and contestable. Treating rarity as a prompt for ethical attention, rather than a reason for invisibility, is a minimal requirement for socially responsive HTA. Future Perspectives Future research should examine topic selection practices across diverse HTA settings, particularly in resource-limited contexts. Comparative studies and policy evaluations could identify enablers and barriers to implementing equity-oriented frameworks at this early stage. More empirical work is also needed to assess whether such reforms meaningfully influence which technologies are prioritised and whose needs are addressed. Limitations This article is policy focused and opinion driven rather than a systematic review, which may limit comprehensiveness. Only English-language publications were included, potentially omitting relevant local or grey literature, especially from LMICs. Evidence is largely conceptual or policy oriented, with limited empirical data on real-world implementation of equity-based topic selection. Additionally, positive case experiences may be over-represented, whilst less successful or abandoned initiatives are under-reported. Acknowledgements The authors have no acknowledgements to declare. Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium. Declarations Funding The authors did not receive support from any organisation for the submitted work. Conflict of interest Authors MM and FH have no conflict of interests to declare. Unrelated to the submitted work, WVP declares grant support from PhRMA Foundation and AbbVie and also declares personal fees and equity holdings from Stage Analytics. References